Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

FBT vs PBE: which is really different?

FBT and PBE hold 53% of their weight in the same names, and FBT returned more over the year.

First Trust NYSE Arca Biotechnology Index Fund and Invesco Biotechnology & Genome ETF.

23.6%FBT in the S&P 500
30.0%PBE in the S&P 500
+48.9%FBT total return, 1 year
+36.2%PBE total return, 1 year

ETFIQ Off-Index Score: FBT scores higher

How much of it is not the index it is sold as an alternative to?

FBT 64.1PBE 61.70.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

FBT76% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
24%76%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 39% of the fund · 31 holdings filed Sep 18, 2026 · Nasdaq-100: 16% in24%76%inoutside the S&P 500active share 99% · top ten 39% of the fund
PBE70% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
30%70%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 47% of the fund · 33 holdings filed Sep 19, 2026 · Nasdaq-100: 20% in30%70%inoutside the S&P 500active share 99% · top ten 47% of the fund

53% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, FBT and PBE hold 53% of their money in the same securities at the same weight.

Positions FBT and PBE both hold, largest shared weight first
HoldingFBTPBE
Natera, Inc.4.24%5.70%
Illumina, Inc.3.90%5.53%
Regeneron Pharmaceuticals, Inc.3.66%4.89%
Gilead Sciences, Inc.3.58%5.27%
Biogen Inc.3.35%5.07%
Amgen Inc.3.29%4.53%
Vertex Pharmaceuticals Incorporated3.24%4.77%
Sarepta Therapeutics, Inc.3.29%3.01%
Exelixis, Inc.3.20%2.91%
Halozyme Therapeutics, Inc.4.57%2.91%
TG Therapeutics, Inc.3.08%2.91%
Repligen Corporation3.80%2.76%
Only in each
Only in FBTOnly in PBE
NeoGenomics, Inc. 4.37%Royalty Pharma PLC 4.88%
Corcept Therapeutics Inc. 3.72%Novavax Inc 3.03%
Genmab A/S (ADR) 3.71%QIAGEN NV 2.81%
BeOne Medicines Ltd. (ADR) 3.64%Moderna Inc 2.75%
argenx SE (ADR) 3.50%Protagonist Therapeutics Inc 2.69%
BioNTech SE (ADR) 3.25%AnaptysBio Inc 2.68%
Bruker Corporation 3.17%Vericel Corp 2.62%
Bio-Techne Corporation 3.14%Ardelyx Inc 2.56%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 19, 2026.

Performance, window by window

FBT and PBE over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
FBTPBEFBTPBEFBTPBE
3 months+17.2%+13.2%+14.9 pts+11.0 pts+19.6 pts+15.7 pts
6 months+40.6%+25.9%+22.6 pts+7.8 pts+16.4 pts+1.6 pts
1 year+48.9%+36.2%+32.3 pts+19.6 pts+27.1 pts+14.4 pts
3 years+80.7%+65.0%+2.3 pts−13.4 pts−17.5 pts−33.1 pts
Since launch+848.2%+492.4%+44.6 pts−311.1 pts−842.1 pts−1197.8 pts
Open the live comparison on ETFIQ
FBT and PBE on the same fields, as of Sep 18, 2026. Source: ETFIQ.
FBT
First Trust NYSE Arca Biotechnology Index Fund
Holds 31 stocks in biotech, 24% of its weight in S&P 500 companies
PBE
Invesco Biotechnology & Genome ETF
Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies
IssuerFirst TrustInvesco
ThemeBiotechBiotech
In the S&P 50023.6%30.0%
Active share vs the S&P 50099.1%99.0%
In the Nasdaq-10016.2%19.5%
Holdings3133
Top ten, share of the fund39.2%46.7%
Expense ratio0.55%0.59%
Fee for the differing part0.55%0.60%
Total return, 1 year+48.9%+36.2%
vs the S&P 500+32.3 pts+19.6 pts
vs the Nasdaq-100+27.1 pts+14.4 pts
Below its high−2.1%−3.9%
Net assets$2.9bn$414m

FBT in plain words

By weight, 24% of FBT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 39% of the fund across 31 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +48.9% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 32.3 pts.

PBE in plain words

By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.

Questions people ask

Do FBT and PBE hold the same stocks?
By their latest filings, 53% of their books are the same securities at the same weight, which is close to holding one of them twice. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, FBT or PBE?
FBT has 24% of its weight in S&P 500 names and PBE has 30%, so FBT differs more from the index.
Which is cheaper, FBT or PBE?
FBT charges 0.55% a year and PBE charges 0.59%, so FBT is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

FBT against PBE, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, FBT against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/fbt-vs-pbe Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources